ESMO/X
Dec 7, 2024, 10:48
Use of the ESMO-Magnitude of Clinical Benefit Scale for HTA Recommendations
Fabrice Andre shared a post on X:
“One key mission of ESMO is to deliver Frameworks that shape the oncology practice: mcbs, escat, etac-s etc .
In this paper, a high ESMO-Magnitude of Clinical Benefit Scale was associated with faster HTA decisions.
Authors: Erica Visintin, Aris Angelis.”
Fabrice André is a prominent medical oncologist specializing in breast cancer. He holds the position of Director of the Research Division at Gustave Roussy Cancer Center and Professor of Medicine at the University Paris Saclay. Professor André also chairs the biomarker group at UNICANCER (the French cooperative group). He is the President-Elect of the European Society for Medical Oncology (ESMO).
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 1, 2025, 19:24
Aug 1, 2025, 19:14
Aug 1, 2025, 18:32